VAX-31
Invasive Pneumococcal Disease (Adults)
Key Facts
About VaxCyte
VaxCyte is pioneering the development of broad-spectrum bacterial vaccines to address significant unmet medical needs in pneumococcal disease, Group A Strep, and Shigella infections. Their cell-free protein synthesis platform enables the production of high-fidelity vaccines with enhanced immunogenicity and broader serotype coverage than conventional approaches. The company's lead candidate VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in clinical development, designed to cover over 95% of invasive pneumococcal disease in adults aged 50 and older. With three Phase 3 trials underway and topline data expected in Q4 2026, VaxCyte is well-positioned to potentially set a new standard of care in pneumococcal vaccination.
View full company profileAbout VaxCyte
VaxCyte is pioneering the development of broad-spectrum bacterial vaccines to address significant unmet medical needs in pneumococcal disease, Group A Strep, and Shigella infections. Their cell-free protein synthesis platform enables the production of high-fidelity vaccines with enhanced immunogenicity and broader serotype coverage than conventional approaches. The company's lead candidate VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in clinical development, designed to cover over 95% of invasive pneumococcal disease in adults aged 50 and older. With three Phase 3 trials underway and topline data expected in Q4 2026, VaxCyte is well-positioned to potentially set a new standard of care in pneumococcal vaccination.
View full company profile